Navigation Links
Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
Date:9/4/2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...
(Date:12/3/2009)... the design of the upcoming forest deal at Copenhagen in ... at the University of Leeds. , Writing today in ... 50% of the carbon credit payments to be agreed at ... should be made to forest dwellers directly, and their property ...
(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...
Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 1Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 2Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 3Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 4Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 5Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 6Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 7Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 1Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 2Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 3Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 1Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 2
... (IL-2), an immune-boosting drug used experimentally in HIV therapy, ... system T cells in some HIV-positive people who respond ... of Health (NIH) Clinical Center and the National Institute ... NIH. A report describing the study, led by the ...
... heart attack and unstable angina patients placed on beta-blocker ... to a study by researchers at Washington University School ... Heart Institute in Kansas City. The study appears in ... the American Medical Association. , "In our investigation of ...
... of 72 cases of monkeypox in the United States ... fatality, even though the disease usually kills 10 percent ... patients die? New research from Saint Louis University Health ... answer. , In this month's issue of Virology, researcher ...
Other Biology News:HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 2HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 3Survival of heart patients on beta-blockers varies greatly with genetic variation 2Survival of heart patients on beta-blockers varies greatly with genetic variation 3Survival of heart patients on beta-blockers varies greatly with genetic variation 4Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly 2
(Date:12/2/2009)... TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... in a dose confirmation and dosimetry trial of Cotara® ... form of brain cancer. Cotara is a targeted ... a potential new treatment for GBM. Cotara specifically ...
(Date:12/2/2009)... Netherlands, December 2 Pepscan Holding NV,the Netherlands based ... of immune therapeutics today announced that it,has appointed Wim ... Dr. Mol will be responsible ... and strategic direction of the company. He brings to,Pepscan ...
(Date:12/2/2009)... today announced data presentations on its novel oral JAK2 ... Annual Meeting and Exposition in New Orleans. ,, Data ... Phase 1 dose-escalation trial of SB1518 detailing its safety, ... from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)... - AEterna Zentaris Inc. (NASDAQ: AEZS ; ... focused on endocrine therapy and oncology, today announced ... has granted Fast Track designation for the Company,s ... treatment of relapsed/refractory multiple myeloma. Keryx Biopharmaceuticals, Inc. ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...
... At Third Wave Technologies, former vice president Kevin Conroy ... Puisis, who was CEO since mid-2004 and previously held other ... to Third Wave and stayed for a specific purpose," Puisis ... an upgraded, highly-skilled management team in place, that purpose has ...
... Third Wave Technologies ' compensation in a patent lawsuit ... legal fees. Stratagene is proceeding with its appeal. , ... found that Stratagene willfully infringed on two patents covering ... million. , ,Third Wave uses the technology in its ...
Other Biology Technology:Madison wireless deal goes forward with Cellnet 2
... sizes available for use with 96- or 384-well PCR ... for ease of location on 96-tube plates End ... skirt of the plate* Efficient sealing is achieved ... conjunction with screw or clip-down hot lid thermal cyclers ...
... as a wash buffer for Michels Transport Fluid ... for transportation of specimens (such as renal biopsies ... may remain in Transport Fluid for up to ... Fluid is not a fixative and is not ...
... Biotin Streptavidin-HRP Systems provide rapid, precise ... antigens in frozen or paraffin-embedded tissue, ... systems also facilitate double or triple ... performed simultaneously with primary antibodies of ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
Biology Products: